BIOMERICA INC (BMRA) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US09061H4065
BIOMERICA INC financials
| Fiscal year | 2025 | 2026 |
|---|---|---|
| Revenue | 5.31 m USD | 4.45 m USD |
| Gross profit | 498,000.00 USD | 362,000.00 USD |
| Operating income | -5.14 m USD | -5.32 m USD |
| EBIT | -4.97 m USD | -3.75 m USD |
| Net income | -4.97 m USD | -3.78 m USD |
| Diluted EPS – continuing operations | -2.16 USD | -1.30 USD |
Full history since 1986, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About BIOMERICA INC
Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing of diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases in North America, Asia, Europe, the Middle East, and South America. The company offers diagnostic test kits are used to analyze blood, urine, nasal, or fecal material from patients to aid in the diagnosis of diseases, food intolerances, and other medical conditions, as well as detect and measure the presence and levels of specific bacteria, hormones, antibodies, antigens, and other substances that may exist in the human body at extremely low concentrations through clinical laboratories and in point-of-care settings, including physicians' offices and over-the-counter channels. It also provides contract development and manufacturing services to third parties. In addition, the company commercializes inFoods IBS product through physician-directed and laboratory-based channels, such as third-party reimbursement pathways. Further, it is involved in the development and optimization of immunoassays, enzyme-linked immunosorbent assays, rapid diagnostic tests, and related diagnostic technologies; and research, development, commercialization of diagnostic-guided therapy (DGT) products to treat gastrointestinal diseases, such as irritable bowel syndrome (IBS), and other inflammatory diseases. Additionally, the company offers EZ detect colon disease home test; Aware Breast Self-Exam product; and hp+detect, a diagnostic test designed to detect Helicobacter pylori (H. pylori) bacteria in the gastrointestinal tract. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
More stocks
- NATURAL HEALTH TRENDS CORP (NHTC)
- SCIENTIFIC INDUSTRIES INC (SCND)
- Verde Clean Fuels, Inc. (VGAS)
- ADM ENDEAVORS, INC. (ADMQ)
- BioCorRx Inc. (BICX)
- Childrens Place, Inc. (PLCE)
- Zeo ScientifiX, Inc. (ZEOX)
- Kaixin Holdings (KXIN)
- Stimcell Energetics Inc. (STME)
- FibroBiologics, Inc. (FBLG)
- OneMeta Inc. (ONEI)
- INNOVATIVE FOOD HOLDINGS INC (IVFH)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.